EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immune checkpoint inhibition in ovarian cancer

Junzo Hamanishi, Masaki Mandai, Ikuo Konishi

International Immunology · 01.07.2016 · 28 (7) · 339-348

DOI: 10.1093/intimm/dxw020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunology, online erschienen am 07.04.2016. Verfasst von Junzo Hamanishi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Jap…. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies have shown that tumor cells acquire escape mechanisms to evade host immunity in the tumor microenvironment. Two key immune checkpoint pathways mediated by immunosuppressive co-signaling, the first via programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-1/PD-L1) and the second via CTLA-4 and B7 (CTLA-4/B7), have been previously described. Several clinical trials have revealed an outstanding anti-tumor efficacy of immune checkpoint inhibitors (anti-CTLA-4 antibody, anti-PD-1 antibody and/or anti-PD-L1 antibody) in patients with various types of solid malignancies, including non-small cell lung cancer, melanoma, renal cell cancer and ovarian cancer. In this review, we examine pre-clinical studies that described the local immune status and immune checkpoint signals in ovarian cancer, highlight recent clinical trials that evaluated immune checkpoint inhibitors against ovarian cancer and discuss the clinical issues regarding immune checkpoint inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsAntibodies, MonoclonalB7-H1 AntigenCTLA-4 AntigenClinical Trials as TopicDrug Evaluation, PreclinicalFemaleHumansImmunotherapyLymphocyte ActivationOvarian NeoplasmsProgrammed Cell Death 1 ReceptorTreatment OutcomeTumor Escape

Stichwörter der Autor:innen

CTLA-4PD-1PD-L1biomarkerimmunotherapy

Substanzen

Antibodies, MonoclonalB7-H1 AntigenCTLA-4 AntigenCTLA4 protein, humanPdcd1 protein, mouseProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan jnkhmns@kuhp.kyoto-u.ac.jp.
  • Department of Obstetrics and Gynecology, Kinki University, Higashiosaka, Osaka, 577-8502, Japan.
  • Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

Zitieren

APA

Hamanishi, J., Mandai, M., & Konishi, I. (2016). Immune checkpoint inhibition in ovarian cancer. International Immunology, 28(7), 339-348. https://doi.org/10.1093/intimm/dxw020

Vancouver

Hamanishi J, Mandai M, Konishi I. Immune checkpoint inhibition in ovarian cancer. International Immunology. 2016;28(7):339-348. doi:10.1093/intimm/dxw020

BibTeX
@article{Hamanishi2016,
  author = {Hamanishi, Junzo and Mandai, Masaki and Konishi, Ikuo},
  title = {Immune checkpoint inhibition in ovarian cancer},
  journal = {International Immunology},
  year = {2016},
  volume = {28},
  number = {7},
  pages = {339--348},
  doi = {10.1093/intimm/dxw020}
}
Kostenlos starten →